Time to prerandomization monthly seizure count in perampanel trials

Objective: To determine whether a novel endpoint of time to prerandomization monthly seizure count could be used to differentiate efficacious and nonefficacious therapies in clinical trials of new add-on antiepileptic drugs (AEDs). Methods: This analysis used data from 3 randomized, double-blind, placebo-controlled phase III trials of perampanel as an add-on therapy in patients with epilepsy who were experiencing refractory partial seizures: studies 304 (ClinicalTrials.gov identifier NCT00699972), 305 (NCT00699582), and 306 (NCT00700310). Time to prerandomization monthly seizure count was evaluated post hoc for each trial, and findings were compared with the original primary outcomes (median percent change in seizure frequency and 50% responder rate). Outcomes were assessed for all partial-onset seizures, secondarily generalized (SG) tonic-clonic seizures only, and complex partial plus SG (CP + SG) seizures. Results: Perampanel 4–12 mg significantly prolonged median time to prerandomization monthly seizure count, generally by more than 1 week, compared with placebo, across all 3 studies, consistent with the original primary outcomes. Analysis of SG seizures only, and CP + SG seizures, also indicated a significantly prolonged median time to prerandomization monthly seizure count with perampanel 8 mg and 12 mg compared with placebo. Conclusions: Time to prerandomization monthly seizure count is a promising novel alternative to the standard endpoints of median percent change in seizure frequency and 50% responder rates used in trials of add-on AEDs. Use of this endpoint could reduce exposure to placebo or ineffective treatments, thereby facilitating trial recruitment and improving safety.

[1]  Roth Sh.  Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. , 1998 .

[2]  P. Ryvlin,et al.  Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials , 2011, The Lancet Neurology.

[3]  A. Beydoun,et al.  Oxcarbazepine monotherapy for partial-onset seizures , 2000, Neurology.

[4]  A. Sólyom,et al.  Dose‐dependent Safety and Efficacy of Zonisamide: A Randomized, Double‐blind, Placebo‐controlled Study in Patients with Refractory Partial Seizures , 2005, Epilepsia.

[5]  B. Steinhoff,et al.  Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305 , 2013, Epilepsia.

[6]  G. Krauss,et al.  Adjunctive perampanel for refractory partial-onset seizures , 2012, Neurology.

[7]  S. Shorvon,et al.  Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. , 2000, Epilepsia.

[8]  John A. Messenheimer,et al.  Lamotrigine XR Conversion to Monotherapy: First Study Using a Historical Control Group , 2011, Neurotherapeutics.

[9]  E. Ben-Menachem,et al.  Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating Monotherapy , 2000 .

[10]  Simon Shorvon,et al.  Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial Seizures , 2000 .

[11]  F. Dreifuss,et al.  Levetiracetam for partial seizures , 2000, Neurology.

[12]  Steve S. Chung,et al.  Lacosamide as adjunctive therapy for partial‐onset seizures: A randomized controlled trial , 2010, Epilepsia.

[13]  G. Krauss,et al.  Adjunctive perampanel for refractory partial-onset seizures , 2012 .

[14]  C. Elger,et al.  Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study , 2009, Epilepsia.

[15]  S. Roth.  Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. , 1998, The Journal of rheumatology.

[16]  R. Leroy,et al.  Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy , 2011, Neurology.

[17]  E. Ben-Menachem,et al.  Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures , 2007, Epilepsia.

[18]  Theodore Holmes Bullock,et al.  Revisiting the Concept of Identifiable Neurons , 2000, Brain, Behavior and Evolution.

[19]  A. Gil-Nagel,et al.  Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures , 2009, Acta neurologica Scandinavica.

[20]  W. Alves,et al.  Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures , 2007, Neurology.

[21]  E. Ben-Menachem,et al.  Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy , 2010, Epilepsy Research.

[22]  E. Ben-Menachem,et al.  Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. , 2000, Epilepsia.

[23]  Simon Shorvon,et al.  Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies , 2013, Epilepsia.

[24]  J. Sackellares,et al.  Randomized, Controlled Clinical Trial of Zonisamide as Adjunctive Treatment for Refractory Partial Seizures , 2004, Epilepsia.

[25]  C. Elger,et al.  Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy , 2010, Neurology.

[26]  P. Halász,et al.  Adjunctive lacosamide for partial‐onset seizures: Efficacy and safety results from a randomized controlled trial , 2009, Epilepsia.

[27]  G. Pledger,et al.  Alternative analyses for antiepileptic drug trials. , 1993, Epilepsy research. Supplement.

[28]  G. Pledger,et al.  Clinical Trials of Investigational Antiepileptic Drugs: Monotherapy Designs , 1991, Epilepsia.